


neurophet[™]



Visualization of PET Tracer Uptake and
SUVR Quantification

neurophet SCALE PET

MFDS(Korea) Approved

US-FDA 510(k) cleared


PMDA(Japan) Approved

HSA(Singapore) Approved


neurophet SCALE PET

From Visualization ————— to Quantification

Amyloid*




Tau*



- SUVR for Tau PET staging (Braak stage ROIs & Temporal meta ROIs)
- [^{18}F]Flortaucipir, [^{18}F]MK-2640, [^{18}F]PI-2620 etc


Dopamine*



- Specified for striatum
- Asymmetry index
- Supportive for differential diagnosis of Parkinsonism (IPD, MSA, PSP) and ET

*Upcoming Release

Tracer-based options can be used for research only depending on the national regulation.




3D render image

Centiloid scale

^{11}C PiB, ^{18}F Flutemetamol, ^{18}F Florbetaben, ^{18}F Florbetapir, ^{18}F NAV4694

**Automatic & Accurate
SUVR
Quantification**

FDG*



- Specified for ROIs of Neurodegenerative disorders

General*



- Accurate values for 100+ ROIs with or without MRI registration

Features

neurophet SCALE PET



Tracer-Specific Reports

- **Amyloid:** Centiloid scale
- **Tau:** Braak stage's ROI, Temporal meta ROI
- **Dopamine:** Asymmetry index
- **FDG:** Neurodegeneration's Prior ROI
- **General:** Compatible with various PET radiotracers



Enhanced Analysis Workflow

- PET scan & MR image registration
- PET scan & CT image registration
- PET scan only analysis
- Optional: PVC(Partial-Volume Correction)



User-friendly Interface


- User-defined reference region setting
- Opacity & Color range control in viewer
- Easily downloaded analysis result in PDF, CSV



Inter-operation with PACS

- Automated data transfer
- Different user accessibilities depending on authorized permission levels

Fast & Accurate neurophet SCALE PET Analysis




	MRI SEGMENTATION BY BRAIN REGIONS	REGISTRATION METHOD	FULL ANALYSIS TIME
CONVENTIONAL METHOD	8 hours	Manual	8 hrs or more
neurophet SCALE PET	1 min	Fully Automatic	10-15 min

Above features are underdevelopment

Neurophet SCALE PET supports clinical decision

Concordance of interpretation


Amyloid PET ¹⁾



	AUC	ACC	SEN	SPEC
Neurophet SCALE PET	0.9593	0.9633	0.9412	0.9774

Reference region: Pons (Cut-off: 0.61)

Tau PET ²⁾



	ACC
Neurophet SCALE PET	0.822

Reference region: Cerebellar cortex (Cut-off: 1.05) / A Priori ROI

Inter-rater Kappa on Amyloid PET positivity³⁾

*Validated in 3 university hospitals


*Compared with the standard reference determined with the agreement between two raters

***Rater 1:** Experienced Nuclear Medicine (≥ 10 years) / **Rater 2:** General Nuclear Medicine (≤ 3 years)

Site 1

Florbetaben
(N=119)


Rater 1 (Experienced NM)
Rater 2 (General NM)



Site 2

Flutemetamol
(N=128)


Rater 1 (Experienced NM)
Rater 2 (General NM)



Site 3

Flutemetamol
(N=100)

Rater 1 (Experienced NM)
Rater 2 (General NM)



Overcome brain disorders
with advanced neuroscience



NEUROPHET Inc.
12F, 124, Teheran-ro, Gangnam-gu, Seoul,
Republic of Korea

T. +82 2 6954 7971
F. +82 2 6954 7972
E. contact@neurophet.com

www.neurophet.com

© 2023 NEUROPHET Inc., All rights reserved.

